Merck
Making it count: Key innovations on show at this year’s Interphex meeting, day 1
With a spring in their step, manufacturing experts from pharma and biotech descend on New York to enjoy the offerings from this year’s Interphex meeting. Here’s our brief round-up of what to see from exhibitors at the event on day one… more
Merck to partner with Jenner Institute to speed up vaccine availability
Science and technology company, Merck, has partnered with Oxford University’s Jenner Institute to develop cost-effective vaccine manufacturing processes, aimed at speeding up vaccine availability. more
Merck collaborates with Medisafe on digital offering to help with adherence
Merck has revealed its collaboration with US-based Medisafe, which is aimed at helping cardiometabolic patients better manage medication intake and adherence to prescribed treatment regimens through a digital offering. more
Merck wins Best Bioprocessing Supplier award for second year running
Science and technology company, Merck, has been named as the overall ‘Best Bioprocessing Supplier’ at the Asia-Pacific Bioprocessing Excellence Awards where it also won the sub-category of ‘Best Bioprocessing Supplier Award for Single-use Systems’. more
Cladribine tablets now available for certain Scottish patients with MS
The Scottish Medicines Consortium (SMC) has issued its final advice, recommending restricted use of cladribine tablets (Mavenclad, Merck) for the treatment of highly active relapsing multiple sclerosis (MS). more
Merck set to be top in pharma licensing deals for 2018, according to GlobalData
Data and analytics company, GlobalData, has revealed its prediction that Merck will lead the way in licensing deals for the year when considering the success of the company since 2016. more
CE-marked liquid biopsy tests launched by Biocartis
Two CE-marked IVD liquid biopsy tests have been launched by molecular diagnostics company, Biocartis Group. — the Idylla ctKRAS Mutation Test and the Idylla ctNRAS-BRAF Mutation Test. more
MSD to make landmark investment in UK economy with launch of UK hub
Ahead of the government’s announcement of its industrial strategy, it has been revealed that MSD (also known as Merck) will make a landmark investment into the UK’s economy through the opening of a new UK hub, for the research into future treatments. more
The top five tweets: From biotech to the budget — what did EPM readers click on this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
MS patients in England will have access to Mavenclad thanks to commercial agreement
Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. more
Real-world data show clinical effectiveness of golimumab
Real-world data presented by Merck have demonstrated the long-term clinical effectiveness of golimumab (Simponi) for the treatment of rheumatic diseases. more
The top five tweets: From Merck to BioLive — what did EPM readers rate this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
Merck reveals losses in sales due to cyber-attack
Merck has revealed, in its third quarter earnings report, that the manufacturing disruptions related to the cyber-attack that happened earlier in the year led to $135 million in lost sales. more
Merck invests in Italian biotech manufacturing site
Science and technology company, Merck, is investing €35 million in a new production line for the aseptic filling of biotech medicines under isolator at its Bari, Italy, manufacturing site. more
Cladribine tablets now available for MS patients in the UK and Ireland
Science and technology company, Merck, has announced the availability of Mavenclad (cladribine tablets) in the UK and Ireland for the treatment of adults with highly active relapsing multiple sclerosis (MS). more
Instruments of change: Exploring technological advancements and their use in healthcare
In this article, François Feig, head of Global General Medicine and Endocrinology, Merck, explores technological advancements in healthcare and how they can be used to improve patients’ lives. more
Berlin start up chosen for accelerator programme
A Berlin start-up company, labfolder, has been selected to participate in Merck’s Accelerator programme for three months. more
The top five tweets: From Merck’s CEO to gut-on-a-chip — what have EPM readers enjoyed this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
Merck’s CEO, first of three chiefs to quit Trump’s council of business leaders
After the Charlottesville protests over the weekend, during which one woman was killed and several others injured, three business leaders have quit Trump’s council as a result of him not taking a harder stance on the issue. more
Merck & AstraZeneca entering strategic oncology collaboration
Following disappointing announcements this week concerning the unmet primary endpoints of their Phase III trials, Merck and AstraZeneca have today revealed they are entering a strategic oncology collaboration. more
